VA, California Panels Urge Costly Hepatitis C Drugs For Sickest Patients
OldenSlow said
Apr 17, 2014
Tig,
Yeah.. a lot to process. I saw those percentages you mentioned referenced as part of the Pillar 2B trial, which was Simeprevir + Peg/Riba. There were 386 enrolled in that. If you were talking about another section, you'll have to point me to it. I already got a headache. ;)
wayne
Tig said
Apr 17, 2014
Hi Wayne,
Thanks for the links. It's going to take awhile to absorb it all, as they are lengthy reads. I have done an initial review of the CTAF report and find it to be very interesting indeed. The rates of success (SVR) in the recent SOC's, Boc and TVR appear to hold a consensus agreement of 1% relapse at SVR12 but it does indicate a reduction in that rate to 2-2.5% past 1 year. I haven't seen that documented before. It will be interesting to see how they came to that conclusion and the number of participants referenced. One thing is certain, organizations like this will continue to have endless opportunities and interest in their findings. I find looking at their resources as a good place to start.
Tig
OldenSlow said
Apr 17, 2014
"Doctors should consider expensive new hepatitis C drugs for patients with advanced liver disease, including those awaiting transplants, but ask most others to wait for drugs in development, the Department of Veterans Affairs said Wednesday."
"A California panel made similar recommendations Monday, saying in a report to insurers, providers and consumers that immediate treatment with the new drugs, Sovaldi and Olysio, should be given to those with advanced disease, but could be delayed for others."
Tig,
Yeah.. a lot to process. I saw those percentages you mentioned referenced as part of the Pillar 2B trial, which was Simeprevir + Peg/Riba. There were 386 enrolled in that. If you were talking about another section, you'll have to point me to it. I already got a headache. ;)
wayne
Hi Wayne,
Thanks for the links. It's going to take awhile to absorb it all, as they are lengthy reads. I have done an initial review of the CTAF report and find it to be very interesting indeed. The rates of success (SVR) in the recent SOC's, Boc and TVR appear to hold a consensus agreement of 1% relapse at SVR12 but it does indicate a reduction in that rate to 2-2.5% past 1 year. I haven't seen that documented before. It will be interesting to see how they came to that conclusion and the number of participants referenced. One thing is certain, organizations like this will continue to have endless opportunities and interest in their findings. I find looking at their resources as a good place to start.
Tig
"Doctors should consider expensive new hepatitis C drugs for patients with advanced liver disease, including those awaiting transplants, but ask most others to wait for drugs in development, the Department of Veterans Affairs said Wednesday."
"A California panel made similar recommendations Monday, saying in a report to insurers, providers and consumers that immediate treatment with the new drugs, Sovaldi and Olysio, should be given to those with advanced disease, but could be delayed for others."
Kaiser Health News Article